Cite
HARVARD Citation
Middleton, M. et al. (n.d.). 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts. Journal for immunotherapy of cancer. p. A257. [Online].